Compare LCTX & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | IBEX |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 383.7M |
| IPO Year | 1996 | 2017 |
| Metric | LCTX | IBEX |
|---|---|---|
| Price | $1.51 | $28.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $6.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.1M | 98.2K |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.26 |
| EPS | N/A | ★ 1.65 |
| Revenue | $14,556,000.00 | ★ $558,273,000.00 |
| Revenue This Year | $55.75 | $13.14 |
| Revenue Next Year | $2.96 | $5.67 |
| P/E Ratio | ★ N/A | $17.29 |
| Revenue Growth | ★ 53.24 | 9.77 |
| 52 Week Low | $0.37 | $21.64 |
| 52 Week High | $2.09 | $42.99 |
| Indicator | LCTX | IBEX |
|---|---|---|
| Relative Strength Index (RSI) | 33.23 | 35.77 |
| Support Level | $0.94 | $27.70 |
| Resistance Level | $1.84 | $30.64 |
| Average True Range (ATR) | 0.11 | 0.87 |
| MACD | -0.04 | 0.21 |
| Stochastic Oscillator | 2.06 | 9.57 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.